Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 12/20 | 0.47 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.44 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2589516 | 0.85 | LMNA (0.49) | OPRM1OPRD1OPRK1 | |
| SCHEMBL2590397 | 0.85 | ADAM17 (0.49) | ADAM17KDM1A | |
| Hydrochloric Acid SCHEMBL2590334 | 0.84 | LMNA (0.48) | OPRM1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL2586592 | 0.84 | LTA4H (0.46) | OPRM1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL2577021 | 0.83 | OPRM1 (0.56) | OPRM1OPRD1OPRK1 | |
| SCHEMBL2581589 | 0.83 | ADAM17 (0.43) | OPRM1ADAM17OPRK1KDM2B | |
| Hydrochloric Acid SCHEMBL2581407 | 0.79 | OPRM1 (0.42) | OPRM1OPRD1OPRK1KDM2BKDM1A | |
| SCHEMBL12175450 | 0.75 | OPRM1 (0.53) | OPRM1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL2589490 | 0.74 | OPRM1 (0.53) | OPRM1OPRD1OPRK1 | |
| SCHEMBL14713320 | 0.74 | OPRM1 (0.57) | OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859777-B2 | 4-fluoro-4-arylpiperdin-1-yl derivatives as mu opioid function moderators | KINENTIA BIOSCIENCES LLC (US) | 2014-10-14 | — | — | US | disclosed |
| US-20130045165-A1 | 4-FLUORO-4-ARYLPIPERDIN-1-YL DERIVATIVES AS MU OPIOID FUNCTION MODERATORS | KINENTIA BIOSCIENCES, LLC (US) | 2013-02-21 | — | — | US | disclosed |
| WO-2011137331-A2 | 4-FLUORO-4-ARYLPIPERDIN-1-YL DERIVATIVES AS MU OPIOID FUNCTION MODERATORS | KINENTIA BIOSCIENCES LLC (US) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045165-A1 | 4-FLUORO-4-ARYLPIPERDIN-1-YL DERIVATIVES AS MU OPIOID FUNCTION MODERATORS | OPRD1, OPRK1, OPRM1 | OPRM1 3/4885ADAM17 4036/4885OPRD1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.